The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.
PMID: 21646480
2011
Antimicrobial agents and chemotherapy
Abstract: Population sequencing of the entire reverse transcriptase (RT) gene identified L74V, F77L, and L214F mutations in the polymerase domain and K476N and V518I mutations in the RNase H domain.
Abstract: Single-genome sequencing analyses of the selected virus revealed a complex population of mutants that all contained L74V and L214F linked to other mutations, including ones not identified during population sequencing.
Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase.
Method: RT mutations were identified from the International AIDS Society USA Drug (IAS-USA) mutation tables, spring 2008 (http://www.iasusa.org/resistance_mutations): M41L, K65R, D67N, insertion 69, K70R/E, L74I/V, L100I, K103N, V106A/M, V108I, Q151M, Y181I/C, M184V, Y188C/L, G190A/S, L210W, T215Y/F, PMID: 22180722
2011
Romanian biotechnological letters
Result: 19.5% of the patients presented L74V/I mutation that occur in patients with virologic failure while receiving non-TAM regimens and causes intermediate resistance to DDI and ABC, and a slight increase in susceptibility to AZT and TDF.
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
PMID: 20007333
2010
The Journal of antimicrobial chemotherapy
Abstract: Apricitabine shows antiviral activity in vitro against HIV-1 strains and clinical isolates with mutations in the reverse transcriptase that confer resistance to other NRTIs, including M184V, thymidine analogue mutations (TAMs), nucleoside-associated mutations such as L74V and certain mutations at codon 69.
N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
Method: The K70R, L74V, Y181C, M184V and N348I mutations were introduced into the wild-type (WT) p6HRT-Prot prokaryotic expression vector by site-directed mutagenesis using the QuikChange mutagenesis kit (Stratagene La Jolla, CA).
Method: The WT, K70R, Y181C, N348I, K70R/Y181C, K70R/Y181C/N348I, K70R/L74V, K70R/L74V/N348I,
Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.
Introduction: As observed for the K65R variant, virus containing the L74V mutation remained sensitive to zidovudine.
Introduction: Selection studies showed a delayed emergence of HIV-1-resistant viruses to DXG, which was associated with K65R or L74V mutations in MT-2 cells.
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
Abstract: Addition of the nucleoside resistance mutations L74V or M41L+T215Y to K101E+G190S improved fitness and abolished EFV-dependent stimulation of replication.
Table: L74V
Figure: Impact of the nucleoside resistance mutation L74V on replication by (K101E+G190S) NL4-3 in the absence and presence of EFV.
Discussion: L74V, in addition to improving the fitness of Discussion: It is unclear at present how both L74V and TAMs might reduce or eliminate EFV-dependent stimulation; this effect appears independent of the effects of these nucleoside resistance mutations on EFV IC50.
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
PMID: 20462946
2010
The Journal of antimicrobial chemotherapy
Method: We also examined the extent to which the 52 NNRTI-selected mutations covaried with mutations at 12 major nucleoside reverse transcriptase inhibitor (NRTI) resistance positions, including M41L, K65R, D67N, T69S_SS, K70E, K70R, L74V, L74I, V75M/T, Y115F, Q151M, M184V/I, L210W, T215F and T215Y.
Result: The strongest positive correlations were bet
Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs.
HIV mutation literature information.
PMID: 
2011
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT